Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31586750 | 0.75 | TDP1 (0.43) | KDM4EALDH1A1GLAHPGDSMN1; SMN2 | |
| SCHEMBL21809020 | 0.75 | TRPM5 (0.33) | KDM4EALDH1A1GLAHPGDSMN1; SMN2 | |
| SCHEMBL29419880 | 0.75 | TRPM5 (0.33) | KDM4EALDH1A1GLAHPGDSMN1; SMN2 | |
| SCHEMBL24609261 | 0.71 | ALDH1A1 (0.31) | KDM4EALDH1A1HPGD | |
| SCHEMBL30251875 | 0.70 | ALDH1A1 (0.37) | KDM4EALDH1A1GLAHPGDSMN1; SMN2 | |
| SCHEMBL23858817 | 0.70 | ALDH1A1 (0.37) | KDM4EALDH1A1GLAHPGDSMN1; SMN2 | |
| SCHEMBL29324081 | 0.69 | ADORA2A (0.32) | KDM4ESMN1; SMN2TRPA1 | |
| SCHEMBL17813455 | 0.68 | KDM1A (0.31) | — | |
| SCHEMBL7928093 | 0.68 | CYP1A2 (0.39) | KCNH2 | |
| SCHEMBL29419891 | 0.68 | CYP1A2 (0.39) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | KDM4E 3365/4885ALDH1A1 252/4885GLA 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.